Buy tag for Elan ahead of MS drug review

DESPITE a 15% dip in its share price in the last week, Goodbody Stockbrokers has put a buy tag on Elan.

Buy tag for Elan ahead of MS drug review

The share price jumped ahead by over 3% on Tuesday when it emerged a US committee is to review the company’s suspended multiple sclerosis drug Tysabri.

However, the shares ended the day down.

Already a subscriber? Sign in

You have reached your article limit.

Subscribe to access all of the Irish Examiner.

Annual €130 €80

Best value

Monthly €12€6 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited